Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
Stage 4 Neuroblastoma
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients With Refractory/Recurrent Neuroblastoma|
- MTD defined as the highest dose level tested at which 0/6 or 1/6 patients experience dose-limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) criteria, version 4.0 [ Time Frame: Up to 28 days ] [ Designated as safety issue: Yes ]All toxicities observed will be summarized in terms of type (organ affected or laboratory determination), severity (by NCI CTCAE), and attribution. Tables will be created to summarize these toxicities and side effects by dose level and by course as well as with Kaplan-Meier plots (i.e. time to first delay or dose reduction) in order to assess the tolerability of the regime over multiple courses.
- Recommended phase II dose [ Time Frame: Up to 28 days ] [ Designated as safety issue: No ]
- Changes in levels of HACA (or other genotype) and tumor response [ Time Frame: Baseline to up to 3 years ] [ Designated as safety issue: No ]
- Changes in the levels of T cells, NK cells, monocytes, cytokines, and chemokines [ Time Frame: Baseline to up to 28 days ] [ Designated as safety issue: No ]These levels and the changes relative to baseline will be summarized by dose level by simple summary statistics: means (possibly after transformation) or medians, ranges, and standard deviations (if numbers and distribution permit). Scatterplots will be used to explore possible associations between the dose and day and toxicity experienced (as reflected in the maximum grade of toxicity experienced, infections or platelet recovery).
- Changes in TLDA scores [ Time Frame: Baseline to up to 3 years ] [ Designated as safety issue: No ]Standard descriptive summaries as well as scatterplots will be used. The association between the changes in TLDA scores and overall tumor response will also be summarized graphically and quantitatively. Changes (from baseline) in the TLDA scores over the course of treatment will be plotted and summarized by dose level and course.
- Event-free survival [ Time Frame: From the start of treatment with lenalidomide until progression, clinical deterioration mandating that the patient terminate treatment or death due to any cause, whichever occurs first, assessed up to 3 years ] [ Designated as safety issue: No ]Will be summarized with Kaplan-Meier plots.
- Overall response [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]The association between the changes in TLDA scores and overall tumor response will be summarized graphically and quantitatively.
- Overall survival [ Time Frame: From start of lenalidomide until death for any reason or date that patient was last known to be alive if the patient is still alive, assessed up to 3 years ] [ Designated as safety issue: No ]Will be summarized with Kaplan-Meier plots.
- Pharmacokinetic determinations of lenalidomide [ Time Frame: Baseline, at 60 and 90 minutes, at 2, 6, 24 hours and days 7 and 22 after last dose of lenalidomide in course 1 ] [ Designated as safety issue: No ]These will be summarized by dose level with simple summary statistics: means (possibly after transformation) or medians, ranges, and standard deviations (if numbers and distribution permit). Scatterplots will be used to explore possible associations between the dose and estimates of the pharmacokinetic parameters, and between the pharmacokinetic determinations and toxicity experienced (as reflected in the maximum grade of toxicity experienced or in clinical measurements).
|Study Start Date:||February 2013|
|Estimated Primary Completion Date:||December 2016 (Final data collection date for primary outcome measure)|
Experimental: Treatment (lenalidomide, dinutuximab, isotretinoin)
Patients receive lenalidomide PO QD on days 1-21, dinutuximab IV over 10 hours on days 8-11, and isotretinoin PO BID on days 15-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Other Names:Drug: Isotretinoin
Other Names:Other: Laboratory Biomarker Analysis
Correlative studiesDrug: Lenalidomide
Other Names:Other: Pharmacological Study
Hide Detailed Description
I. To determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of lenalidomide in combination with fixed doses of ch14.18 (dinutuximab) given intravenously (IV) for four days (days 8-11) and isotretinoin given twice each day orally for 14 days (days 15-28) and repeated every 28 days to children with refractory or recurrent neuroblastoma.
II. To define the toxicities of lenalidomide administered in combination with ch14.18 and isotretinoin.
III. To describe the differences in immune function modulation between "low" versus "high" dose lenalidomide given with ch14.18 and isotretinoin.
I. To determine the pharmacokinetics of lenalidomide given in this combination regimen.
II. To determine the steady state pharmacokinetics of isotretinoin (day 28, course one) given in combination with lenalidomide.
III. To measure peak and trough levels of ch14.18 in patients receiving lenalidomide and to compare to historical controls of patients receiving ch14.18 in combination with interleukin 2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).
IV. To describe the immunological effects of lenalidomide (T cells, natural killer [NK] cells, monocytes, cytokines, chemokines) within this three drug regimen.
V. To define the incidence and titers of human anti-chimeric antibody (HACA) on this regimen.
VI. To describe, within the context of a phase I study, the response rate to lenalidomide combined with ch14.18 and isotretinoin in patients with recurrent/refractory neuroblastoma.
VII. To summarize, within the context of a phase I study, the event-free survival of patients with recurrent/refractory neuroblastoma or in complete response (CR) after progressing, and who are treated with lenalidomide combined with ch14.18 and isotretinoin.
VIII. To determine, within the context of a phase I study, if killer-cell immunoglobulin-like receptor (KIR) receptor-ligand mismatch or specific Fc gamma receptor (Fc gamma R) alleles are associated with anti-tumor response.
IX. To quantify neuroblastoma tumor cell "load" using a 5-gene TaqMan Low Density Array (TLDA) assay in peripheral blood at study entry, following, with each disease evaluation and at end of therapy and bone marrow at study entry, with each response evaluation when bone marrow is sampled, and at end of therapy.
X. To compare the toxicities of this regimen with the historical toxicity data from the Children's Oncology Group (COG) ANBL0032 and ANBL0931 studies of ch14.18 with IL-2, GM-CSF and isotretinoin.
XI. To describe the tolerability and ability to give full doses of ch14.18 and lenalidomide over extended periods of time, i.e. in courses 6-12.
OUTLINE: This is a dose-escalation study of lenalidomide.
Patients receive lenalidomide orally (PO) once daily (QD) on days 1-21, dinutuximab IV over 10 hours on days 8-11, and isotretinoin PO twice daily (BID) on days 15-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up periodically.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01711554
|United States, California|
|Children's Hospital Los Angeles||Recruiting|
|Los Angeles, California, United States, 90027|
|Contact: Araz Marachelian 323-361-8573 firstname.lastname@example.org|
|Principal Investigator: Araz Marachelian|
|Lucile Packard Children's Hospital Stanford University||Recruiting|
|Palo Alto, California, United States, 94304|
|Contact: Neyssa M. Marina 650-723-5535 email@example.com|
|Principal Investigator: Neyssa M. Marina|
|UCSF Medical Center-Parnassus||Recruiting|
|San Francisco, California, United States, 94143|
|Contact: Katherine K. Matthay 415-476-0603 firstname.lastname@example.org|
|Principal Investigator: Katherine K. Matthay|
|United States, Colorado|
|Children's Hospital Colorado||Recruiting|
|Aurora, Colorado, United States, 80045|
|Contact: Margaret E. Macy 720-777-8856 Margaret.email@example.com|
|Principal Investigator: Margaret E. Macy|
|United States, Georgia|
|Children's Healthcare of Atlanta - Egleston||Recruiting|
|Atlanta, Georgia, United States, 30322|
|Contact: Kelly C. Goldsmith 404-727-2655 firstname.lastname@example.org|
|Principal Investigator: Kelly C. Goldsmith|
|United States, Illinois|
|University of Chicago Comer Children's Hospital||Recruiting|
|Chicago, Illinois, United States, 60637|
|Contact: Susan L. Cohn 773-702-2571 email@example.com|
|Principal Investigator: Susan L. Cohn|
|United States, Massachusetts|
|Boston Children's Hospital||Recruiting|
|Boston, Massachusetts, United States, 02115|
|Contact: Suzanne Shusterman 617-632-4901 firstname.lastname@example.org|
|Principal Investigator: Suzanne Shusterman|
|United States, Michigan|
|C S Mott Children's Hospital||Recruiting|
|Ann Arbor, Michigan, United States, 48109|
|Contact: Gregory A. Yanik 734-746-3243 email@example.com|
|Principal Investigator: Gregory A. Yanik|
|United States, New York|
|Memorial Sloan-Kettering Cancer Center||Recruiting|
|New York, New York, United States, 10065|
|Contact: Stephen S. Roberts 212-639-4034 firstname.lastname@example.org|
|Principal Investigator: Stephen S. Roberts|
|United States, Ohio|
|Cincinnati Children's Hospital Medical Center||Recruiting|
|Cincinnati, Ohio, United States, 45229|
|Contact: Brian D. Weiss 513-636-9863 email@example.com|
|Principal Investigator: Brian D. Weiss|
|United States, Pennsylvania|
|Children's Hospital of Philadelphia||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: Yael P. Mosse 215-590-0965 firstname.lastname@example.org|
|Principal Investigator: Yael P. Mosse|
|United States, Texas|
|Cook Children's Medical Center||Recruiting|
|Fort Worth, Texas, United States, 76104|
|Contact: Mary Meaghan P. Granger 682-885-4007 email@example.com|
|Principal Investigator: Mary Meaghan P. Granger|
|United States, Washington|
|Seattle Children's Hospital||Recruiting|
|Seattle, Washington, United States, 98105|
|Contact: Julie R. Park 206-987-1947 firstname.lastname@example.org|
|Principal Investigator: Julie R. Park|
|Hospital for Sick Children||Recruiting|
|Toronto, Ontario, Canada, M5G 1X8|
|Contact: Sylvain Baruchel 416-813-7795 email@example.com|
|Principal Investigator: Sylvain Baruchel|
|Principal Investigator:||Araz Marachelian||New Approaches to Neuroblastoma Treatment (NANT)|